Services
Build equity story & lead Seed and Series A fundraisings
Find partners for strategic deals
Build business plans & corporate
development strategy
Perform competitive analysis & optimize drug positioning
Structure your team and governance with the right people at the right time
Biotech companies
You need customized and hands-on accompaniment to transform and accelerate your company journey ?
​
Jérémie leverages its dual experience (entrepreneur & investor) and professional network to unlock the potential of your company.
​
Jérémie can consider various relationships going from strategic advisor or coach to CEOs, to Board member.
Evaluate the potential of therapeutic innovations
Define critical R&D milestone and derisking steps across maturation process
Elaborate early-stage company road-map up to Seed funding
Conduct scientific, intellectual property, and business due diligence
Shape drug development programs and create New Co
Run early-stage companies up to critical milestones
Venture capital firms
You need external analysis to build your investment thesis and better inform your investment decision ?
​
Jérémie leverages its experience in Seed funding venture capital firm to enhance your due diligence.
Jeremie's expertise encompasses immunology, inflammation, auto-immunity, gastro-enterology and rheumatology.
Tech Transfer Offices
You need to shape and derisk early-stage R&D projects to prepare the launch of a New Co ?
​
Jérémie leverages its experience in early-stage venture capital firm to guide you through this process.
​
Jérémie can perform purpose-based consulting or consider leadership consulting role up to CEO
on-boarding.
Customers Testimonials
Competitive landscape analysis
"Jérémie has advised us on a focused mission on the competition landscape in one of our disease areas of interest. Definitely great help which was fully comprehensive and useful to the team !"
​
Joel Crouzet, CEO
Ermium Therapeutics is a series A biotechnology company developing innovative therapies for auto-immune diseases.
Corporate strategy
Jérémie was asked to lead a targeted business development action to explore potential licensing deal followed by broader strategic analysis on Medsenic optionalities. We particularly appreciated his efficiency to deliver this work in a timely manner.
​
Veronique Pomi, Deputy CEO
Medsenic merged to Bone Therapeutics to form Biosenic, an innovative company addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair
Tridek-One is a private biotechnology company founded in 2018, based on groundbreaking research by our scientific founders at INSERM, Paris on the role of CD31 in the modulation of the immune response.